The Pharmacy Times® Asthma resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Patients can breathe easier knowing that their local pharmacists are ideally positioned to help them manage their allegy, asthma and COPD conditions.
Previous research has found illicit opiates may exacerbate asthma.
Inhaler misuse may result in more asthma attacks.
Some may remember the old formulation of OTC Primatene Mist that was taken off the market in 2011 because it contained chlorofluorocarbon (CFC) propellants, which are known to deplete the ozone layer.
The FDA announced approval of Wixela Inhub on January 30, 2019.
Pulmatrix is set to launch a clinical investigation on the product in 2019.
With new products coming to the pharmacy market, such as smart devices and digital medicines, the profession will need to develop quickly to keep up pace.
Mylan's drug is approved for 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg doses.
The generic drug (Wixela Inhub, Mylan) is indicated to treat patients with asthma and chronic obstructive pulmonary disease, including bronchitis and emphysema.
Teva has just unveiled the world's first integrated smart inhaler to the market.
The FDA has approved dupilumab (Dupixent, Regeneron and Sanofi) in patients with moderate-to-severe asthma aged 12 years and older